drugset / Trial / NCT05896527
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
Phase 2
Completed
229 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment
Summary
This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.
Timeline
- Start
- 2023-05-02
- Primary completion
- 2024-03-25
- Completion
- 2024-03-25
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs DC-806 800 mg BID; p = 0.0164; Odds Ratio (OR) 3.59 (95% CI 1.15 to 12.37); Fisher Exact NCT05896527 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-806 | Unknown | 200 mg | Oral |
| Subject | DC-806 | Unknown | 400 mg | Oral |
| Subject | DC-806 | Unknown | 600 mg | Oral |
| Subject | DC-806 | Unknown | 800 mg | Oral |